United Therapeutics drug improves lung hypertension

United Therapeutics will share positive Phase 3 data for ralinepag, a drug that showed clinical improvement in lower-risk pulmonary arterial hypertension. The results will be presented at the European Society of Cardiology and European Respiratory Society Congresses in late 2026.